| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.947789 |
| 003 | CaOODSP |
| 005 | 20250428091713 |
| 006 | m o d f |
| 007 | cr mn||||||||| |
| 008 | 250206e20250313onc ob f000 0 eng d |
| 020 | |a9780660756226 |q(statement) |
| 020 | |a9780660756233 |q(summary) |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 043 | |an-cn--- |
| 086 | 1 |aHP40-384/2025E-PDF |
| 086 | 1 |aHP40-384/2025-1E-PDF |
| 245 | 00|aUpdated guidance on respiratory syncytial virus (RSV) vaccines for older adults including the expanded use of RSVPreF3 for individuals 50-59 years of age and use of the new mRNA-1345 vaccine. |
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cMarch 13, 2025. |
| 264 | 4|c©2025 |
| 300 | |a1 online resource (51 pages) + |esummary (5 pages) |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |aIssued also in French under title: Directives mises à jour sur les vaccins contre le virus respiratoire syncytial (VRS) chez les personnes âgées, y compris l'utilisation élargie du VRSPreF3 chez les individus de 50 à 59 ans et l'utilisation du nouveau vaccin ARNm-1345. |
| 500 | |aOn cover: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI). |
| 500 | |a"Pub.: 240852"--Page 2. |
| 500 | |a"Pub.: 240854"--Page 2 (summary). |
| 504 | |aIncludes bibliographical references (pages 47-51). |
| 650 | 0|aRespiratory syncytial virus|xVaccination|xGovernment policy|zCanada. |
| 650 | 0|aViral vaccines|xGovernment policy|zCanada. |
| 650 | 0|aImmunization of older people|xGovernment policy|zCanada. |
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
| 775 | 08|tDirectives mises à jour sur les vaccins contre le virus respiratoire syncytial (VRS) chez les personnes âgées, y compris l'utilisation élargie du VRSPreF3 chez les individus de 50 à 59 ans et l'utilisation du nouveau vaccin ARNm-1345.|w(CaOODSP)9.947790 |
| 856 | 40|qPDF|s871 KB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-384-2025-eng.pdf|z(statement) |
| 856 | 40|qPDF|s222 KB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/HP40-384-2025-1-eng.pdf|z(summary) |
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-updated-guidance-rsv-vaccines-older-adults-including-expanded-use-rsvpref3-individuals-50-59-years-age-use-new-mrna-1345-vaccine.html|z(statement) |
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-rsv-vaccines-older-adults-including-expanded-use-rsvpref3-individuals-50-59-years-age-use-new-mrna-1345-vaccine.html|z(summary) |